HomeCompareMTP vs JNJ

MTP vs JNJ: Dividend Comparison 2026

MTP yields 701.51% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MTP wins by $924938.18M in total portfolio value
10 years
MTP
MTP
● Live price
701.51%
Share price
$0.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$924938.20M
Annual income
$722,372,390,440.71
Full MTP calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — MTP vs JNJ

📍 MTP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTPJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTP + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTP pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTP
Annual income on $10K today (after 15% tax)
$59,628.20/yr
After 10yr DRIP, annual income (after tax)
$614,016,531,874.60/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, MTP beats the other by $614,016,531,170.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTP + JNJ for your $10,000?

MTP: 50%JNJ: 50%
100% JNJ50/50100% MTP
Portfolio after 10yr
$462469.11M
Annual income
$361,186,195,634.24/yr
Blended yield
78.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MTP
No analyst data
Altman Z
-17.1
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTP buys
0
JNJ buys
0
No recent congressional trades found for MTP or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTPJNJ
Forward yield701.51%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$924938.20M$20.0K
Annual income after 10y$722,372,390,440.71$827.78
Total dividends collected$908543.22M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MTP vs JNJ ($10,000, DRIP)

YearMTP PortfolioMTP Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$80,851$70,150.82$10,676$355.77+$70.2KMTP
2$616,581$530,070.28$11,407$389.39+$605.2KMTP
3$4,437,682$3,777,940.56$12,198$426.53+$4.43MMTP
4$30,160,247$25,411,927.64$13,056$467.62+$30.15MMTP
5$193,682,255$161,410,790.66$13,987$513.12+$193.67MMTP
6$1,175,972,185$968,732,172.36$14,998$563.56+$1175.96MMTP
7$6,755,308,275$5,497,018,037.06$16,098$619.52+$6755.29MMTP
8$36,739,695,007$29,511,515,151.87$17,295$681.69+$36739.68MMTP
9$189,313,837,689$150,002,364,032.24$18,599$750.82+$189313.82MMTP
10$924,938,196,768$722,372,390,440.71$20,022$827.78+$924938.18MMTP

MTP vs JNJ: Complete Analysis 2026

MTPStock

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Full MTP Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this MTP vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTP vs SCHDMTP vs JEPIMTP vs OMTP vs KOMTP vs MAINMTP vs ABBVMTP vs MRKMTP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.